Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

186 trials with published results (36%)

Research Maturity

400 completed trials (78% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

4.3%

22 terminated out of 516 trials

Success Rate

94.8%

+8.3% vs benchmark

Late-Stage Pipeline

46%

239 trials in Phase 3/4

Results Transparency

47%

186 of 400 completed with results

Key Signals

186 with results95% success22 terminated

Data Visualizations

Phase Distribution

437Total
Not Applicable (53)
P 1 (48)
P 2 (97)
P 3 (135)
P 4 (104)

Trial Status

Completed400
Unknown38
Terminated22
Recruiting22
Withdrawn20
Active Not Recruiting8

Trial Success Rate

94.8%

Benchmark: 86.5%

Based on 400 completed trials

Clinical Trials (516)

Showing 20 of 20 trials
NCT04702789Phase 4Terminated

Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.

NCT07325240Phase 4Recruiting

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

NCT04024293Not ApplicableRecruiting

Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry

NCT07082816Phase 3CompletedPrimary

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

NCT07390890Recruiting

DSLT for Reducing Medication in Glaucoma

NCT06689696Completed

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring

NCT04499248Phase 1Recruiting

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT07217678Phase 4Recruiting

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

NCT05273385Not ApplicableTerminated

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

NCT06144918Phase 2Completed

Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

NCT07335211Phase 3Recruiting

Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

NCT06394973Phase 2Completed

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT06629649Not ApplicableRecruiting

Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

NCT05902871Not ApplicableRecruiting

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

NCT06441643Phase 2Completed

Next Generation Rocklatan

NCT07218783Phase 3Recruiting

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

NCT07218796Phase 3Recruiting

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

NCT04500574Phase 1Terminated

Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension

NCT07210216Not Yet Recruiting

GLAUcoma Diagnostic and Imaging Analysis (GLAUDIA) Study

NCT03798223Not ApplicableActive Not Recruiting

Optimal Treatment Protocol for Selective Laser Trabeculoplasty

Scroll to load more

Research Network

Activity Timeline